Cargando…
Study on myelin injury of AD mice treated with Shenzhiling oral liquid in the PI3K/Akt–mTOR pathway
Shenzhiling oral liquid (SZL) is a Traditional Chinese Medicine (TCM) compound to be approved by the China Food and Drug Administration (CFDA) (Z20120010) for the treatment of mild-to-moderate Alzheimer’s disease (AD). However, its mechanism in early AD is not clear. We studied its mechanism in prot...
Autores principales: | Wang, Yahan, Chen, Fang, Wang, Pengwen, Mana, Lulu, Sheng, Ning, Huang, Shuaiyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262987/ https://www.ncbi.nlm.nih.gov/pubmed/32462951 http://dx.doi.org/10.1177/2058738420923907 |
Ejemplares similares
-
Shenzhiling Oral Liquid Protects STZ-Injured Oligodendrocyte through PI3K/Akt-mTOR Pathway
por: Liu, Zhenhong, et al.
Publicado: (2020) -
Potential synaptic plasticity‐based Shenzhiling oral liquid for a SAD Mouse Model
por: Wang, Yahan, et al.
Publicado: (2019) -
PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011) -
Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017) -
The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
por: Su, Hengchuan, et al.
Publicado: (2013)